BiPER Therapeutics is a biotech company established in 2021. Its area of specialization is the discovery and marketing of new treatment plans. The company is unique because it is developing therapies that overstress cancer cells with the hope of treating patients. Its lead candidate, BPR001, is a novel small-molecule drug candidate solely focused on targeting BiP, an oncogenic protein implicated in cancer progression.